Medtronic (NYSE:MDT)-backed Glooko’s platform is designed to integrate data from blood glucose monitors and other devices with either an Apple (NSDQ:AAPL) iPhone or Google (NSDQ:GOOG) Android application. Food intake, medication and insulin dosage can also be recorded to provide context for changes in blood glucose readings. Data from meters and devices is sent to Glooko’s cloud-based Population Tracker, where patients and providers alike can view and analyze the data, and make decisions about interventions and treatments.
Insulet and Glooko, which announced their deal last summer, said the “Insulet Provided Glooko” system allows patients and healthcare providers to view and share data from their OmniPod devices on mobile devices and computers. Providers can download data from multiple devices and remotely monitor patients to detect oiut-of-range glucose levels or other clinical incidents, the companies said.
“A critical component of diabetes management is the ability for patients, as well as their healthcare providers, to see a complete picture of their health,” Insulet president & CEO Patrick Sullivan said in prepared remarks. “Having the ability to track and analyze information about a patient’s insulin data, in combination with blood glucose levels, diet and exercise data, allows patients and their care teams to optimize and improve their healthcare management. We are pleased to partner with Glooko as Insulet’s preferred data management partner and are thrilled to offer Glooko’s award-winning diabetes management platform with our OmniPod system.”
In March 2015, Glooko closed a $16.5 million Series B round that included new investors Medtronic, Canaan Partners and existing backers The Social + Capital Partnership and Samsung Electronics (LON:BC94). Proceeds were slated to expand the company’s reach to insulin pumps, CGM devices and the integration of personalized predictive algorithms.